KDCA "Will secure budget for domestic mRNA vaccine dev."

Announced plans to secure the budget, citing Japan's case of domestic vaccine production

Plans to finalize the organization of a support team for mRNA vaccine development

The Korea Disease Control and Prevention Agency (KDCA) plans to secure national budget for developing domestic mRNA vaccines.

The Korea Disease Control and Prevention Agency (KDCA) announced that they will focus on securing national budget to develop Korea-made mRNA vaccines and secure platforms, supporting up to phase 3 trials.

 

Its vision is to secure domestic mRNA technology based on Japan's case.

 

Japan designated companies that could develop domestic vaccines during the COVID-19 pandemic from 2020 to 2023 and invested KRW 930 billion in the entire process from the beginning of the development, clinical trials, and production.

 

The KDCA has submitted this plan to the Health and Welfare Committee of the National Assembly on July 24th.

 

The KDCA explained that they set a government-wide policy to develop mRNA vaccines and secure platforms.

 

They are in the process of allocating the relevant budget.

 

They also planned this project to allocate a sufficient budget by continuing to communicate with fields, including experts, conferences with companies, and interviews.

 

In particular, the KDCA emphasized that they prioritize securing a multi-KRW 100 billion budget so that they could support up to phase 3 trials by referencing Japan's domestic mRNA vaccine development case.

 

The agency aims to support companies by acquiring budgets based on Japan's KRW 930 billion investment in the development.

 

Additionally, they stated that they are continuing to hold meetings with the Ministry of the Interior and Safety to set up a support team for mRNA vaccine development.

 

Furthermore, they stated that discussions and communications, including conferences with companies and interviews, to establish a system for technology collaboration.

 

The KDCA said, "We will work to secure a sufficient budget with an aim to complete mRNA vaccine development." They added, "As the budget allocation is in progress and the project details are being discussed, we will quickly organize a supporting team within the second half of the year." "When the project takes off, we will officially organize an operating committee with public-private experts and company officials," the KDCA added.

 

"It will allow companies to share their difficulties in their field.

 

We will also supply various technology support packages for vaccine development to research agencies such as the National Institute of Infectious Diseases."